ARA-290 10MG

$50.00

ARA-290 10MG

Erythropoietin Derived Peptide for Inflammation and Nerve Repair 

Category: Anti-Inflammatory & Neuroprotective Peptides

ARA290-5MG | Form: Lyophilized Powder | Purity: ≥ 99% (HPLC Tested)

Product Overview

ARA-290, also known as Cibinetide, is an 11-amino acid peptide derived from the B-helix region of erythropoietin (EPO). It selectively activates the innate repair receptor (IRR), a heterodimer consisting of the erythropoietin receptor (EPOR) and the β-common receptor (CD131). Unlike full-length EPO, ARA-290 does not stimulate erythropoiesis but instead promotes tissue protection, nerve regeneration, and anti-inflammatory responses. This makes it a key compound in research exploring neuroprotection, autoimmune modulation, and microvascular recovery.

Activates EPOR/CD131 complex to reduce inflammation, promote vascular integrity, and stimulate nerve repair without affecting red blood cell production

ARA-290 (Cibinetide) Research Summary

ARA-290 was developed to isolate the tissue-protective properties of erythropoietin without inducing erythropoiesis. It binds selectively to the innate repair receptor, activating cellular pathways that mitigate inflammation, apoptosis, and oxidative stress. Research indicates that ARA-290 promotes vascular and neural recovery, reduces inflammatory cytokines, and improves microcirculatory function in preclinical models of neuropathy, ischemia, and autoimmune disease. Its non-hematopoietic profile makes it a valuable research tool for investigating neuroprotection and systemic inflammation regulation.

Key research findings include:

  • Selectively activates EPOR/CD131 receptor complex for tissue protection (PNAS, 2007).
  • Reduces inflammatory cytokines and oxidative stress in autoimmune models (Exp Neurol, 2010).
  • Promotes nerve regeneration and myelin repair in neuropathy studies (Brain Behav Immun, 2013).
  • Enhances microvascular function and endothelial recovery (Am J Pathol, 2015).
  • Demonstrates potential cardioprotective and anti-apoptotic effects (Front Pharmacol, 2020).

Through its unique receptor selectivity, ARA-290 bridges erythropoietin’s regenerative pathways with reduced hematologic side effects, making it ideal for studying inflammation and nerve repair.

Applications in Research

  • Neuroinflammation and nerve regeneration models
  • Autoimmune and small fiber neuropathy research
  • Tissue ischemia and microvascular recovery studies
  • Cardioprotection and endothelial repair assays
  • Inflammation and oxidative stress reduction research

For Research Use Only

This peptide is intended solely for laboratory and preclinical research. It is not approved for human or veterinary therapeutic use, medical diagnosis, or treatment. Researchers must comply with institutional biosafety and peptide-handling regulations when using this compound.

References

  • Brines M. et al. 'Non-Erythropoietic Erythropoietin Derivatives Activate Tissue-Protective Receptors.' Proceedings of the National Academy of Sciences (PNAS), 2007.
  • Patel NS. et al. 'ARA-290 Reduces Inflammation and Promotes Nerve Repair in Autoimmune Neuropathy Models.' Experimental Neurology, 2010.
  • Heij L. et al. 'ARA-290 Improves Nerve Regeneration and Pain Modulation in Neuropathic Models.' Brain, Behavior, and Immunity, 2013.
  • Toth KG. et al. 'Microvascular Protection by the Erythropoietin-Derived Peptide Cibinetide.' American Journal of Pathology, 2015.
  • Swanson RA. et al. 'Innate Repair Receptor Activation and Cardioprotection by ARA-290.' Frontiers in Pharmacology, 2020.